Vaccinia Virus News and Research

RSS

The vaccinia virus is the "live virus" used in the smallpox vaccine. It is a "pox"-type virus related to smallpox. When given to humans as a vaccine, it helps the body to develop immunity to smallpox. The smallpox vaccine does not contain the smallpox virus and it cannot cause smallpox.

Promising antimicrobial agent kills viruses, stimulates immune system

A promising antimicrobial agent already known to kill bacteria can also kill viruses and stimulate the innate immune system, according to researchers at National Jewish Health.

4 Jun 2009

Researchers unlock mystery of potentially fatal reaction to smallpox vaccine

Researchers from the La Jolla Institute for Allergy & Immunology have pinpointed the cellular defect that increases the likelihood, among eczema sufferers, of developing eczema vaccinatum, a severe and potentially fatal reaction to the smallpox vaccine.

25 May 2009

Virus reveals secret to cancer spread

Cancer Research UK scientists studying a virus have unveiled an important clue to understanding how cancer spreads. Their research is published in Nature.

4 Mar 2009

GeoVax's HIV/AIDS human vaccine trials to begin in North and South America

GeoVax Labs, Inc. has announced that the launch of its Phase 2a Human Vaccine Trials will take place in twelve sites across North and South America.

1 Dec 2008

New study indicates smallpox vaccination effective for decades

Although naturally occurring smallpox was eradicated in 1977, there is concern that bioterrorists might obtain smallpox from a laboratory and release it into the population.

30 Nov 2008

Red colobus monkeys in Uganda found to harbor antibodies to an unknown orthopoxvirus

Researchers report this month that red colobus monkeys in a park in western Uganda have been exposed to an unknown orthopoxvirus, a pathogen related to the viruses that cause smallpox, monkeypox and cowpox. Most of the monkeys screened harbor antibodies to a virus that is similar - but not identical - to known orthopoxviruses.

22 Apr 2008

Nasal vaccine for smallpox protects animals against 77 times the potentially lethal dose of smallpox

Scientists at NanoBio Corporation and the University of Michigan have demonstrated their nasally delivered vaccinia vaccine can protect animals against 77 times the potentially lethal dose of smallpox, and without the safety risks of current vaccines for smallpox.

27 Feb 2008

Nanoemulsion vaccines show increasing promise

A novel technique for vaccinating against a variety of infectious diseases - using an oil-based emulsion placed in the nose, rather than needles - has proved able to produce a strong immune response against smallpox and HIV in two new studies.

27 Feb 2008

New discovery, immune cells confront viruses just inside of the lymph node

Vaccines have led to many of the world's greatest public health triumphs, but many deadly viruses, such as HIV, still elude the best efforts of scientists to develop effective vaccines against them. An improved understanding of how the immune system operates during a viral infection is critical to designing successful anti-virus vaccines.

4 Feb 2008

Potential alternative to the existing smallpox vaccine

University of California, Irvine infectious disease researchers have shown the effectiveness of a potential alternative to the existing smallpox vaccine that can replace the current biodefense stockpile for this lethal virus.

8 Jan 2008

FDA approves Acambis smallpox vaccine

Acambis plc (Acambis) has announced that the US Food and Drug Administration (FDA) has approved its ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) vaccine for protection against smallpox.

4 Sep 2007

Phase II study of TroVax vaccine in patients with metastatic colorectal cancer

A therapeutic cancer vaccine has shown effectiveness when given alongside chemotherapy to patients with metastatic colorectal cancer in a phase II trial, according to researchers at Oxford BioMedica (UK) Ltd.

2 Aug 2007

Study of therapeutic vaccine shows promise for metastatic colorectal cancer

1 Aug 2007

Bavarian Nordic granted new European patent on modified vaccinia virus Ankara

The European Patent Organisation (EPO) has granted a patent to Bavarian Nordic which further strengthens its intellectual property position on MVA in Europe.

12 Jul 2007

Common DNA variations underlie susceptibility to fever after smallpox vaccination

Their finding is the first to link individual differences written into the genetic code with a vaccine-related complication, albeit a mild one.

19 Jun 2007

Genetic factors linked to adverse events related to smallpox vaccination

The study, published in the July 15th issue of The Journal of Infectious Diseases, now available online, may have implications for predicting adverse events from other live vaccines. .

17 Jun 2007

Bioinformatics used to advance human disease research

The use of computers to advance human disease research - known as bioinformatics -- has received a major boost from researchers at the La Jolla Institute for Allergy & Immunology (LIAI).

18 Jun 2006

Novel virus entry mechanism could lead to new drugs against poxviruses

Scientists working with Vaccinia virus, the smallpox vaccine, have discovered a novel mechanism that allows poxviruses to enter cells and cause infection.

13 Apr 2006

Immune system protein LL-37 critical in controlling replication of vaccinia virus

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have identified a defect in the immune response of people with the skin condition atopic dermatitis that puts them at risk of developing serious complications following smallpox vaccination.

23 Mar 2006

Potential therapeutic targets against serious side effects of smallpox vaccine

Smallpox is considered a potential terrorist weapon, but millions of people in the United States are currently advised not to get a vaccine to the disease because they are susceptible to developing a severe adverse reaction.

23 Mar 2006